Q4 2024 Nanobiotix SA Earnings Call Transcript
Key Points
- Nanobiotix SA (NBTX) has made significant progress in its collaboration with Johnson & Johnson, including a $2.6 billion deal plus royalties.
- The company has launched a new platform, Curadigm, which is expected to be applicable across multiple therapeutic areas.
- The NANORAY-312 Phase 3 study in head and neck cancer is progressing well, with a transfer to J&J expected to be completed by Q3 2025.
- Nanobiotix SA (NBTX) has extended its cash runway to mid-2026 due to an amended licensing agreement with J&J, reducing its financial obligations.
- The company has received a $20 million milestone payment related to the progress of NANORAY-312, contributing to its financial stability.
- Nanobiotix SA (NBTX) reported a net loss of EUR68.1 million for 2024, a 72% increase from the previous year, primarily due to a one-off negative revenue recognition accounting impact.
- Cash and cash equivalents decreased from EUR75.3 million in 2023 to EUR49.7 million in 2024, indicating a significant cash burn.
- The company faces potential challenges in securing non-dilutive financing options to extend its cash runway into 2027.
- Negative revenue of EUR7.2 million was recognized in 2024 due to the transfer of NANORAY-312 study sponsorship to Janssen.
- R&D expenses increased by 5% to EUR40.5 million in 2024, driven by clinical development activities related to NANORAY-312 and other trials.
Good day, and welcome to the Nanobiotix business update and full-year 2024 financial results conference call. (Operator Instructions) Please be advised that today's conference is being recorded.
At this point, I would turn the call over to Craig West, Senior Vice President of Investor Relations of Nanobiotix. Please go ahead.
Thank you. Good afternoon and good morning, and welcome to the Nanobiotix conference call to discuss our full-year 2024 financial and operational results. Joining me on the call today are Laurent Levy, Co-Founder and Chief Executive Officer; and Bart van Rhijn, Chief Financial and Business Officer. As a reminder, today's call is being webcast and will be available on our website for replay.
On the next slide, slide 2, I would like to remind you that this call will include forward-looking statements, which may include statements regarding the progress, success, and timing of our ongoing and planned clinical trials, collaborations, regulatory filings,
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
